HUP0400455A3 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function and pharmaceutical compositions containing them - Google Patents
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function and pharmaceutical compositions containing themInfo
- Publication number
- HUP0400455A3 HUP0400455A3 HU0400455A HUP0400455A HUP0400455A3 HU P0400455 A3 HUP0400455 A3 HU P0400455A3 HU 0400455 A HU0400455 A HU 0400455A HU P0400455 A HUP0400455 A HU P0400455A HU P0400455 A3 HUP0400455 A3 HU P0400455A3
- Authority
- HU
- Hungary
- Prior art keywords
- modulators
- analogs
- pharmaceutical compositions
- compositions containing
- hormone receptor
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- -1 heterocyclic succinimide compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23351900P | 2000-09-19 | 2000-09-19 | |
US28473001P | 2001-04-18 | 2001-04-18 | |
US28443801P | 2001-04-18 | 2001-04-18 | |
PCT/US2001/019655 WO2002024702A1 (en) | 2000-09-19 | 2001-06-20 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400455A2 HUP0400455A2 (hu) | 2004-06-28 |
HUP0400455A3 true HUP0400455A3 (en) | 2007-10-29 |
Family
ID=27398441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400455A HUP0400455A3 (en) | 2000-09-19 | 2001-06-20 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function and pharmaceutical compositions containing them |
Country Status (36)
Country | Link |
---|---|
US (1) | US20040176324A1 (hu) |
EP (1) | EP1319007B9 (hu) |
JP (1) | JP4966477B2 (hu) |
KR (1) | KR100765670B1 (hu) |
CN (2) | CN1307181C (hu) |
AR (1) | AR035340A1 (hu) |
AT (1) | ATE318822T1 (hu) |
AU (2) | AU6994301A (hu) |
BG (1) | BG107675A (hu) |
BR (1) | BR0113980A (hu) |
CA (1) | CA2423071A1 (hu) |
CZ (1) | CZ2003780A3 (hu) |
DE (1) | DE60117551T2 (hu) |
DK (1) | DK1319007T3 (hu) |
EE (1) | EE200300108A (hu) |
ES (1) | ES2260244T3 (hu) |
GE (1) | GEP20074144B (hu) |
HK (1) | HK1054230B (hu) |
HR (1) | HRP20030305B9 (hu) |
HU (1) | HUP0400455A3 (hu) |
IL (1) | IL155019A0 (hu) |
IS (1) | IS6750A (hu) |
MX (1) | MXPA03002412A (hu) |
MY (1) | MY138531A (hu) |
NO (1) | NO329931B1 (hu) |
NZ (1) | NZ524803A (hu) |
PE (1) | PE20020729A1 (hu) |
PL (1) | PL361707A1 (hu) |
PT (1) | PT1319007E (hu) |
SK (1) | SK4982003A3 (hu) |
TW (1) | TWI305208B (hu) |
UA (1) | UA78686C2 (hu) |
UY (1) | UY26808A1 (hu) |
WO (1) | WO2002024702A1 (hu) |
YU (1) | YU20003A (hu) |
ZA (1) | ZA200302963B (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2413417A1 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040087548A1 (en) * | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
PL206962B1 (pl) | 2001-12-19 | 2010-10-29 | Bristol Myers Squibb Co | Związek heterocykliczny o budowie skondensowanej |
TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
BR0313405A (pt) | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
JP2007505164A (ja) * | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類 |
US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
JP5070054B2 (ja) * | 2005-08-01 | 2012-11-07 | 武田薬品工業株式会社 | 環状アミン化合物 |
JPWO2008007664A1 (ja) * | 2006-07-11 | 2009-12-10 | 武田薬品工業株式会社 | 二環性複素環化合物およびその用途 |
US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
EP2455370A1 (en) | 2009-07-17 | 2012-05-23 | Shionogi&Co., Ltd. | Pharmaceutical product containing lactam or benzene sulfonamide compound |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
KR102559394B1 (ko) | 2018-06-14 | 2023-07-27 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 물질 사용 재발에 사용되는 비근육 미오신 ii 억제제 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
WO2022061226A1 (en) * | 2020-09-19 | 2022-03-24 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting trem-1 |
CN115340483A (zh) * | 2022-08-31 | 2022-11-15 | 南京吉星生物技术开发有限公司 | 一种萘基吡咯啉二酮化合物及其制备方法与它的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
JPS5046697A (hu) * | 1973-08-20 | 1975-04-25 | ||
US5539126A (en) * | 1994-04-20 | 1996-07-23 | Bristol-Myers Squibb Company | Method for preparing homochiral maleimide intermediates, via silylation techniques |
CZ176197A3 (cs) * | 1994-12-22 | 1998-09-16 | Ligand Pharmaceuticals Incorporated | Modulátory steroidových receptorů a způsoby jejich přípravy a použití |
DE69709752T2 (de) * | 1996-06-27 | 2002-07-18 | Ligand Pharm Inc | Androgen rezeptor modulator verbindungen und verfahren |
AU6945898A (en) * | 1997-04-29 | 1998-11-24 | Salk Institute For Biological Studies, The | Methods for identifying ligands for nuclear hormone receptors |
US7101681B1 (en) * | 1997-11-21 | 2006-09-05 | Amgen, Inc. | Nuclear hormone receptor drug screens |
ATE309250T1 (de) * | 1999-09-10 | 2005-11-15 | Novo Nordisk As | Modulatoren der protein tyrosin phosphatase (ptpases) |
CA2413417A1 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
-
2001
- 2001-06-20 CN CNB018189350A patent/CN1307181C/zh not_active Expired - Fee Related
- 2001-06-20 NZ NZ524803A patent/NZ524803A/en unknown
- 2001-06-20 US US09/885,381 patent/US20040176324A1/en not_active Abandoned
- 2001-06-20 EP EP01948503A patent/EP1319007B9/en not_active Expired - Lifetime
- 2001-06-20 MX MXPA03002412A patent/MXPA03002412A/es active IP Right Grant
- 2001-06-20 SK SK498-2003A patent/SK4982003A3/sk unknown
- 2001-06-20 PL PL36170701A patent/PL361707A1/xx unknown
- 2001-06-20 DK DK01948503T patent/DK1319007T3/da active
- 2001-06-20 ES ES01948503T patent/ES2260244T3/es not_active Expired - Lifetime
- 2001-06-20 KR KR1020037004018A patent/KR100765670B1/ko not_active IP Right Cessation
- 2001-06-20 CZ CZ2003780A patent/CZ2003780A3/cs unknown
- 2001-06-20 AU AU6994301A patent/AU6994301A/xx active Pending
- 2001-06-20 BR BR0113980-0A patent/BR0113980A/pt not_active IP Right Cessation
- 2001-06-20 CN CNA200710006341XA patent/CN1995039A/zh active Pending
- 2001-06-20 UA UA2003043564A patent/UA78686C2/uk unknown
- 2001-06-20 EE EEP200300108A patent/EE200300108A/xx unknown
- 2001-06-20 AT AT01948503T patent/ATE318822T1/de active
- 2001-06-20 PT PT01948503T patent/PT1319007E/pt unknown
- 2001-06-20 CA CA002423071A patent/CA2423071A1/en not_active Abandoned
- 2001-06-20 JP JP2002529112A patent/JP4966477B2/ja not_active Expired - Fee Related
- 2001-06-20 AU AU2001269943A patent/AU2001269943B2/en not_active Ceased
- 2001-06-20 GE GE5206A patent/GEP20074144B/en unknown
- 2001-06-20 DE DE60117551T patent/DE60117551T2/de not_active Expired - Lifetime
- 2001-06-20 HU HU0400455A patent/HUP0400455A3/hu unknown
- 2001-06-20 YU YU20003A patent/YU20003A/sh unknown
- 2001-06-20 WO PCT/US2001/019655 patent/WO2002024702A1/en active IP Right Grant
- 2001-06-20 IL IL15501901A patent/IL155019A0/xx unknown
- 2001-06-27 TW TW090115632A patent/TWI305208B/zh not_active IP Right Cessation
- 2001-06-28 MY MYPI20013097A patent/MY138531A/en unknown
- 2001-06-28 AR ARP010103101A patent/AR035340A1/es unknown
- 2001-06-28 UY UY26808A patent/UY26808A1/es not_active Application Discontinuation
- 2001-08-22 PE PE2001000656A patent/PE20020729A1/es not_active Application Discontinuation
-
2003
- 2003-03-18 IS IS6750A patent/IS6750A/is unknown
- 2003-03-19 NO NO20031266A patent/NO329931B1/no not_active IP Right Cessation
- 2003-03-26 BG BG107675A patent/BG107675A/bg unknown
- 2003-04-15 ZA ZA200302963A patent/ZA200302963B/en unknown
- 2003-04-18 HR HR20030305A patent/HRP20030305B9/xx not_active IP Right Cessation
- 2003-09-09 HK HK03106433.9A patent/HK1054230B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400455A3 (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function and pharmaceutical compositions containing them | |
PT1458723E (pt) | Compostos de succinimida heterocíclicos condensados e seus análogos como moduladores dos receptores hormonais nucleares | |
HUP0304055A2 (hu) | Kondenzált heterociklusos szukcinimid-vegyületek és analógjaik és alkalmazásuk nukleáris hormon receptor funkció modulátoraiként | |
HUP0500096A3 (en) | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function, process for producing them and pharmaceutical compositions containing them | |
HUP0402672A3 (en) | Fused cyclic modulators of nuclear hormone receptor function | |
HUP0303165A3 (en) | Fused cyclic compounds as modulators of nuclear hormone receptor function, process for their preparation and pharmaceutical compositions containing them | |
HUP0202814A3 (en) | Androgen receptor modulator compounds and methods for their preparation and pharmaceutical compositions containing them and their use | |
HUP0203841A3 (en) | 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them | |
HUP0204337A3 (en) | Bicyclic androgen and progesterone receptor modulator compounds and pharmaceutical compositions containing them | |
HUP0200761A2 (en) | Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing them and their use | |
HUP0400058A2 (hu) | Kondenzált heterogyűrűs vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0003844A3 (en) | Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them | |
HUP0303103A3 (en) | Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds | |
HUP9701714A3 (en) | Indole derivatives neuropeptide y receptor antagonists, use thereof and pharmaceutical compositions containing these compounds | |
HUP0201243A2 (en) | Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use | |
IL145071A0 (en) | Fused ring compounds and pharmaceutical compositions containing the same | |
HUP0003859A3 (en) | Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use | |
HUP0203638A3 (en) | Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use | |
HUP0203183A3 (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0202932A3 (en) | Heterocyclic compounds and pharmaceutical compositions can be used as chemokine receptor modulators | |
HUP0003198A2 (en) | Thermodynamically stable modification of 1-(4-carbazoly-loxy)-3-[2-(2-(methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it | |
HUP0201714A3 (en) | Substituted heterocyclic compounds and pharmaceutical compositions containing them | |
HUP0103896A3 (en) | Oxygenic heterocyclic compounds pharmaceutical compositions containing them and their use | |
HUP0203332A3 (en) | Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them | |
HUP0200707A3 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |